Vivione Biosciences Inc. (“Vivione” or the “Company”) (TSXV:VBI) today
announced the termination of Ted Moskal as President of Vivione and its
operating subsidiary, Vivione Biosciences, LLC.
“Ted had a long-standing tenure with Vivione, and we appreciate his
contributions,” said Vivione’s Chief Executive Officer, Kevin
Kuykendall. “However, as the Company matured and expanded into other
markets such as clinical and oil & gas, we began to grow the management
team with individuals that were proficient in the areas in which the
Company was moving and it became clear that a change needed to be made.”
Day-to-day responsibilities with the FDA will be assumed by our Chief
Medical Officer, Dr. Matthew Gombrich.
About Vivione
Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture
Exchange listed biosciences company focused on the commercialization of
its proprietary RAPID-B system; an integrated system of hardware,
software and chemical reagents that quickly and accurately identify,
quantify and qualify bacteria and other pathogens in food safety,
bio-therapeutics, clinical, industrial and oil & gas environments. For
more information, visit www.VivioneBiosciences.com.
Cautionary Statements
This news release contains "forward-looking statements" within the
meaning of applicable securities laws. Although Vivione believes that
the expectations reflected in its forward-looking statements are
reasonable, such statements have been based on factors and assumptions
concerning future events that may prove to be inaccurate. These factors
and assumptions are based upon currently available information to
Vivione. Such statements are subject to known and unknown risks,
uncertainties and other factors that could influence actual results or
events and cause actual results or events to differ materially from
those stated, anticipated or implied in the forward-looking statements.
This news release contains forward-looking information relating to the
commercialization and the development of the RAPID-B system and
Vivione’s business and growth. Readers are cautioned to not place undue
reliance on forward-looking statements. The statements in this news
release are made as of the date of this news release and, except as
required by applicable law, Vivione does not undertake any obligation to
publicly update or to revise any of the included forward-looking
statements, whether as a result of new information, future events or
otherwise. Vivione undertakes no obligation to comment on analyses,
expectations or statements made by third-parties in respect of Vivione,
or its financial or operating results or (as applicable), their
securities.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER
(AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE)
ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Copyright Business Wire 2014